Bio-Reference Laboratories Inc

Bio-Reference Laboratories — Merger or Acquisition (June 2015)

13 slides from Bio-Reference Laboratories's merger presentation, Jun 18, 2015

  1. Slide 1: General Overview June 2015

    Slide 1: General Overview June 2015

    General Overview 18 June 2015 Exhibit 99.3

  2. Slide 2: Our Vision: a leading specialty pharmaceutical company

    Slide 2: Our Vision: a leading specialty pharmaceutical company

    Our Vision We are a leading specialty pharmaceutical company To be the leading developer and supplier of highly potent pharmaceutical products for global markets Click above to view EirGen’s expanded facility

  3. Slide 3: Ireland: Fact Sheet

    Slide 3: Ireland: Fact Sheet

    Ireland: Fact Sheet Waterford Cork Dublin • Population 4.2 million • Largest Exporter of Pharmaceuticals in the World, th largest producer. of World’s Top Pharma Companies Located in Ireland • Home to Pharma companies; pharma and biopharma plants are FDA approved. 25,000 direct & 25,000 indirect emp

  4. Slide 4: Business Overview

    Slide 4: Business Overview

    Business Overview A Specialty Pharmaceutical Company Focused on the development and commercial supply of highly potent pharmaceutical products In a purpose built, state of the art, high containment facility

  5. Slide 5: Introductions – EirGen Founders

    Slide 5: Introductions – EirGen Founders

    Introductions – EirGen Founders PATSY CARNEY Chief Executive Officer/ Co-Founder » Co-founded EirGen » Previously Head of Operations and BD for IVAX Ireland (14 years) » Holds a BSc In Industrial Chemistry from University of Limerick and an MBA from University of Limerick TOM BRENNAN Chief Technical

  6. Slide 6: EirGen Key Milestones

    Slide 6: EirGen Key Milestones

    EirGen Founded EirGen Key Milestones 2005 2006 2008 2009 2011 2012 2013 Successful Regulatory Audit OPEN FOR BUSINESS Submission of First Pan EU EirGen License 1. st License Approval in Canada 2. th Oncology product license submitted to US FDA 3. st commercial product launch in EU 1. Two oncology pr

  7. Slide 7: Current Position: where we are now

    Slide 7: Current Position: where we are now

    Current Position: where we are now » 98 employees, all graduates » 31 successful Clinical Studies » 42 countries for commercial product supply » 27 products in R&D » 10 Products filed with US FDA to date, 3 approved » Pan EU CTD Dossiers filed to date and approved » Oncology Products filed with Japa

  8. Slide 8: Current Position: Regulatory Status

    Slide 8: Current Position: Regulatory Status

    Current Position: Regulatory Status » Global license submission strategy » FDA, Aug 2014, no 483’s » IMB (EMA), May 2015, no major observations » Licensed to handle Cytotoxic Materials

  9. Slide 9: Therapeutic Focus

    Slide 9: Therapeutic Focus

    Therapeutic Focus » Oncology Molecules » Immunosuppressants » Prostaglandins » Cytotoxic Molecules » Hormonals » Steroids

  10. Slide 10: Global Presence

    Slide 10: Global Presence

    Category Countries Global Presence Commercial (BLUE) Licenses Pending (ORANGE) Customer Contracts (GREEN)

  11. Slide 11: Existing Business Model

    Slide 11: Existing Business Model

    EirGen Existing Business Model R&D (non- GMP and GMP) Clinical studies and license approval Routine on- going commercial supply Sales, marketing & distribution Strategic Partner

  12. Slide 12: OPKO Opportunities

    Slide 12: OPKO Opportunities

    EirGen OPKO Opportunities » API Vertical Integration - Synergies with OPKO Finetech, Israel » Product Development & Manufacturing - OPKO’s current & future products » Irish based Supply Chain Hub - global distribution of OPKO Products » Tax efficient R&D Hub - proven R&D track record since incorpora

  13. Slide 13: Thank You

    Slide 13: Thank You

    Thank You www.EirGen.com

Source: SEC EDGAR · 425 filed Jun 18, 2015

More decks from Bio-Reference Laboratories Inc